Publication
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMelanomacivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneNRAScivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantNRAS Q61civic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23569304
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Vemurafenib | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID3750In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutation… (full text at CIViC) PMID 23569304 · Trunzer et al., 2013 · Open in CIViC | civic |
| BRAF V600K1 | ||||||||
| Vemurafenib | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID4177In the phase II BRIM-2 trial (NCT00949702), 132 patients with BRAF V600-mutant metastatic melanoma received vemurafenib monotherapy. The overall RECIST v1.1 objective response rate was 53% (70/132), i… (full text at CIViC) PMID 23569304 · Trunzer et al., 2013 · Open in CIViC | civic |
| MAP2K1 E203K1 | ||||||||
| Vemurafenib | Melanoma | Predictive | C | Supports Resistance | — | submitted | EID4728In a retrospective study, of a phase 2 clinical trial (NCT00949702), of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, the MAP2K1 E203K mutation was asso… (full text at CIViC) PMID 23569304 · Trunzer et al., 2013 · Open in CIViC | civic |
| MAP2K1 Q56P1 | ||||||||
| Vemurafenib | Melanoma | Predictive | C | Supports Resistance | — | submitted | EID4727In a retrospective study of a phase 2 clinical trial (NCT00949702), of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, the MAP2K1 Q56P mutation was associ… (full text at CIViC) PMID 23569304 · Trunzer et al., 2013 · Open in CIViC | civic |
| NRAS Q611 | ||||||||
| Vemurafenib | Melanoma | Predictive | B | Supports Resistance | 4 | accepted | EID14Vemurafenib resistance is associated with gain of Q61 mutation in NRAS. PMID 23569304 · Trunzer et al., 2013 · Open in CIViC | civic |